Literature DB >> 25518049

Development of a short questionnaire to assess the quality of life in Crohn's disease and ulcerative colitis.

Laith Alrubaiy1, Wai-Yee Cheung2, Phedra Dodds2, Hayley Anne Hutchings2, Ian Trevor Russell2, Alan Watkins2, John Gordon Williams2.   

Abstract

BACKGROUND AND AIMS: Most of the disease-specific quality of life (QoL) measures for inflammatory bowel disease (IBD) are lengthy and time consuming. None have been established for routine use in clinical practice. We designed this study to develop a short QoL measure in IBD.
METHODS: A 32-item questionnaire, the Crohn's and ulcerative colitis questionnaire (CUCQ)-32 was developed by reviewing the literature of the previously validated questionnaires and by consultation with patients and experts. Construct validity was carried out using the Short Form 12 and the EuroQol 5 dimensions questionnaires and two disease severity measures (the Simple Clinical Colitis Activity Index and the Harvey-Bradshaw Index). Test-retest analysis was done by asking patients to complete the CUCQ questionnaire twice within a period of two weeks.
RESULTS: Data were obtained from 205 patients with IBD who completed the CUCQ-32. Psychometric analysis showed that Cronbach's α was 0.88, item-total correlations were good, and there were no ceiling or flooring effects. Stepwise regression identified eight items that accounted for >95% of the variance in the CUCQ-32. The resulting CUCQ-8 demonstrated good internal consistency (Cronbach's α = 0.84), had good reproducibility (intraclass correlation coefficient = 0.94), was well correlated with the EuroQol 5 dimensions questionnaire (r = 0.58) and the Short Form-12 (r = 0.65 for physical component and r = 0.63 for mental component), and was responsive to change (responsiveness ratio was 0.64, p-value < 0.05).
CONCLUSIONS: CUCQ-8 is a short questionnaire that has the potential to be an efficient tool for assessing the QoL of all patients with IBD in clinical practice.
Copyright © 2014 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Crohn’s disease; Inflammatory bowel disease; colitis; quality of life

Mesh:

Year:  2014        PMID: 25518049     DOI: 10.1093/ecco-jcc/jju005

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  12 in total

Review 1.  Current best practice for disease activity assessment in IBD.

Authors:  Alissa J Walsh; Robert V Bryant; Simon P L Travis
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-09-01       Impact factor: 46.802

2.  Validation of the Crohn's and Ulcerative Colitis questionnaire in patients with acute severe ulcerative colitis.

Authors:  Hayley A Hutchings; Laith Alrubiay; Alan Watkins; W-Y Cheung; Anne C Seagrove; John G Williams
Journal:  United European Gastroenterol J       Date:  2016-09-20       Impact factor: 4.623

3.  Further Validation of the Crohn's and Ulcerative Colitis Questionnaire-32 (CUCQ-32) to Measure the Quality of Life in Patients Treated with Biologics Therapy.

Authors:  Laith Alrubaiy; Rafid Sikafi; Hayley Anne Hutchings; Ian Arnott; John Gordon Williams
Journal:  Clin Pract       Date:  2022-06-10

4.  Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial.

Authors:  John G Williams; M Fasih Alam; Laith Alrubaiy; Ian Arnott; Clare Clement; David Cohen; John N Gordon; A Barney Hawthorne; Mike Hilton; Hayley A Hutchings; Aida U Jawhari; Mirella Longo; John Mansfield; Jayne M Morgan; Frances Rapport; Anne C Seagrove; Shaji Sebastian; Ian Shaw; Simon P L Travis; Alan Watkins
Journal:  Lancet Gastroenterol Hepatol       Date:  2016-09

5.  Physicians Should Provide Shared Decision-Making for Anti-TNF Therapy to Inflammatory Bowel Disease Patients.

Authors:  Jae Myung Cha; Dong Il Park; Sang Hyoung Park; Jeong Eun Shin; Wan Soo Kim; Suk Kyun Yang
Journal:  J Korean Med Sci       Date:  2017-01       Impact factor: 2.153

6.  Disability due to Inflammatory Bowel Disease Is Correlated with Drug Compliance, Disease Activity, and Quality of Life.

Authors:  Jin Young Yoon; Jeong Eun Shin; Sang Hyoung Park; Dong Il Park; Jae Myung Cha
Journal:  Gut Liver       Date:  2017-05-15       Impact factor: 4.519

Review 7.  Inflammatory bowel disease-specific health-related quality of life instruments: a systematic review of measurement properties.

Authors:  Xin-Lin Chen; Liang-Huan Zhong; Yi Wen; Tian-Wen Liu; Xiao-Ying Li; Zheng-Kun Hou; Yue Hu; Chuan-Wei Mo; Feng-Bin Liu
Journal:  Health Qual Life Outcomes       Date:  2017-09-15       Impact factor: 3.186

8.  Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of Interleukin 1 blockade in Acute Severe Colitis: the IASO trial.

Authors:  Martin Geoffrey Thomas; Carrie Bayliss; Simon Bond; Francis Dowling; James Galea; Vipul Jairath; Christopher Lamb; Christopher Probert; Elizabeth Timperley-Preece; Alastair Watson; Lynne Whitehead; John G Williams; Miles Parkes; Arthur Kaser; Tim Raine
Journal:  BMJ Open       Date:  2019-02-15       Impact factor: 2.692

9.  Protocol for faecal microbiota transplantation in ulcerative colitis (FMTUC): a randomised feasibility study.

Authors:  Maki Jitsumura; Andrew Laurence Cunningham; Matthew David Hitchings; Saiful Islam; Angharad P Davies; Paula E Row; Andrew D Riddell; James Kinross; Tom S Wilkinson; G J Jenkins; John G Williams; Dean Anthony Harris
Journal:  BMJ Open       Date:  2018-10-18       Impact factor: 2.692

10.  Systematic Review of Development and Content Validity of Patient-reported Outcome Measures in Inflammatory Bowel Disease: Do We Measure What We Measure?

Authors:  Emma M van Andel; Brechtje D M Koopmann; Femke Crouwel; Casper G Noomen; Nanne K H de Boer; Dirk P van Asseldonk; Lidwine B Mokkink
Journal:  J Crohns Colitis       Date:  2020-09-16       Impact factor: 9.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.